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Abstract 
Transfusion of allogeneic blood products is associated with increased morbidity and 
mortality. Therefore, strategies for reducing transfusion of these products during trauma 
management are valuable. We report a case of severe blunt abdominal trauma, successfully 
treated with antifibrinolytic medication and fibrinogen concentrate. Rotational 
thromboelastometry (ROTEM) was used to identify hyperfibrinolysis and afibrinogenaemia. 
In order to achieve haemostasis, over a 3-hour period the patient received a total of 1 g of 
tranexamic acid, 7 units of packed red blood cells, 16 g of fibrinogen concentrate 
(Haemocomplettan P), 3500 ml of colloids and 5500 ml of lactated Ringer’s solution. Together 
with surgical measures, this treatment stopped the bleeding and stabilised the patient. There 
was no transfusion of either fresh frozen plasma or platelets. The limited need for allogeneic 
blood products is of particular interest, and clinical studies of the approach used here appear 
to be warranted. 
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Introduction 
Trauma is the leading cause of death among children and young adults,1,2 therefore its 
optimal treatment is of utmost importance. European guidelines for the treatment of trauma 
and massive bleeding recommend restoration of circulating volume and intervention to 
control bleeding, followed by therapy with blood products and/or pharmacological agents 
to restore haemostasis.3,4 
Allogeneic blood products are often administered to trauma patients, with the aim of 
increasing levels of haemoglobin, platelets or coagulation factors. There are, however, 
significant drawbacks to using these products such as the need for blood group matching, 
variable constituent concentrations, long administration time and, particularly with fresh 
frozen plasma (FFP), high administration volume and transfusion-related acute lung 
injury.5,6 Transfusion has been associated with increased morbidity and mortality,7,8 and 
methods for reducing transfusion requirements should therefore be pursued. Coagulation 
factor concentrates such as fibrinogen concentrate, factor XIII concentrate and prothrombin 
complex concentrates (PCCs) may in some circumstances be used in place of cryoprecipitate 
or FFP for supplementing coagulation factors. In massive bleeding or trauma, fibrinogen is 
the first coagulation factor to reach critical levels.9,10 Studies show that fibrinogen concentrate 
is effective at increasing clot strength and reducing bleeding in this setting.11-15 
Hyperfibrinolysis is common after trauma and is a direct consequence of both tissue injury 
and shock. As described recently, is mediated in part by de-inhibition of tissue plasminogen 
activator (tPA) through the consumption of PAI-1 by activated protein C. Low levels of PAI-
1, in combination with the increased release of tPA from the vessel wall will result in 
hyperfibrinolysis.16 
Point-of-care coagulation monitoring, such as rotational thromboelastometry (ROTEM) and 
thrombelastography (TEG), is valuable as it assesses the whole clotting process, from fibrin 
formation through to clot retraction and fibrinolysis, at the bedside with minimal delays.17,18 
ROTEM facilitates rapid and accurate detection of coagulopathy and hyperfibrinolysis in 
trauma patients.19 
We report a case of aortic rupture with severe coagulopathy after blunt abdominal trauma, 
where ROTEM-guided administration of antifibrinolytics and fibrinogen concentrate 
minimised the requirement for allogeneic blood products. 
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Case Report 
A healthy, 24-year-old southern European male (75 kg, 175 cm) was crushed at work 
between a wall and a heavy building vehicle weighing over 400 kg, sustaining a severe blunt 
abdominal trauma. The time of the accident was 09:58. Upon arrival at the scene, the 
paramedic team found that the patient was barely responsive (Glasgow coma score [GCS] 
13) and shocked.  Suspecting severe intra-abdominal haemorrhage, an intravenous line was 
placed and volume resuscitation was started. Upon arrival of the emergency physician, the 
patient was immediately transported to our Emergency Department by ambulance (Figure 
1).  
Upon arrival (10:24), the patient presented with insufficient spontaneous respiration, signs of 
severe shock with non-palpable peripheral pulses and a heart rate of 140 beats per minute; 
the GCS was 7.  The patient was manually ventilated while the abdomen was assessed using 
the focused abdominal sonography in trauma (FAST) method. After a few minutes, the 
patient was intubated to obtain a secure airway and at 10:35 an emergency laparotomy was 
performed. The aorta was clamped immediately to control bleeding. Shortly afterwards, the 
patient went into cardiac arrest with pulseless electrical activity (PEA) requiring external 
heart massage. During resuscitation, the internal jugular vein was cannulated and a 2x12 G 
catheter was placed. In this dramatic situation, only three blood samples were taken: one 
sample each for venous blood gas analysis, analysis by ROTEM, and blood typing. The 
venous blood gas analysis showed massive combined metabolic and respiratory acidosis (pH 
6.61, pCO2 11.8, base excess [BE] -29.4 mmol/l, lactate 13 mmol/l).  
To improve the efficiency of resuscitation measures, an emergency thoracotomy was 
performed followed by open heart massage. The aorta was again clamped due to massive 
bleeding without an identifiable source; this and volume resuscitation resulted in the heart 
re-filling.  Because of ventricular fibrillation, two direct defibrillations (30 Joules) were 
administered and further open heart massage was performed. After 2 minutes, a pulse was 
palpable at the carotid artery.  
ROTEM analysis of the initial sample, started at 10:53, indicated excessive hyperfibrinolysis, 
and FibTEM revealed afibrinogenaemia (Figure 2). We immediately (at 11:00) administered 1 
g of tranexamic acid and 4 g of fibrinogen concentrate (Haemocomplettan P) intravenously. 
Overall, the patient had severe coagulopathy due to hyperfibrinolysis as well as loss and 
consumption of coagulation factors, which itself aggravated the massive diffuse bleeding.  
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After this intervention, within a couple of minutes, the diffuse haemorrhage decreased, and 
ROTEM analysis at 11:24 indicated considerable improvement in coagulation (Figure 3).  
Due to persistent afibrinogenaemia (indicated by ROTEM) and continuing haemorrhage, 
between 11:25 and 11:40, an additional 8 g of fibrinogen concentrate was administered. 
Exploration of the abdomen revealed a longitudinal lesion of the aorta, cranial to the 
bifurcation and inframesenterial, including a lesion of the mesenterium. The lesion on the 
aorta was clamped and sutured. Further exploration of the abdomen revealed a lesion of the 
sigmoid colon over the promontorium; a sigma resection was performed. A further 4 g of 
fibrinogen concentrate was administered at 12:30, resulting in definitive correction of the 
coagulopathy (Figure 4). Surgery was then concluded with temporary closure of the 
abdomen using a Bogota vacuum assisted closure (VAC) system. 
In order to achieve haemostasis, over a 3-hour period the patient received a total of 1 g of 
tranexamic acid, 7 units of packed red blood cells, 16 g of fibrinogen, 3500 ml of colloids and 
5500 ml of lactated Ringer’s solution. After surgery, at 13:45, the patient was admitted to the 
surgical intensive care unit in stable condition. His neurological condition was assessed 
during a brief trial of consciousness: the patient was able to open his eyes and move all 
extremities. Haematological analysis, performed at 13:30, showed high international 
normalised ratio (INR) and extended activated partial thromboplastin time (aPTT) (Table 1). 
These results did not seem to correlate with the clinical findings of no on-going haemorrhage 
and adequate ROTEM results, around that time (Figure 4) and in subsequent analyses 
undertaken every 4–6 hours. In view of the patient’s stable condition, no further treatment 
was deemed necessary at that time.  
A blood test performed at 17:45 showed improved INR and aPTT, but low coagulation factor 
activity in relation to reference values of 50–150% (Table 1). Twenty-four hours after the 
accident, ROTEM parameters were normal, but laboratory testing showed persistent 
pathological coagulation (Table 1). The patient remained stable (no volume replacement or 
vasoactive medication necessary) and was no longer haemorrhaging. 
Second-look abdominal surgery was performed 20 hours later without any complications. 
Intraoperative ROTEM analysis showed early stages of hypofibrinogenaemia, but in the 
absence of bleeding this did not require treatment. Coagulation test results were broadly 
similar to those obtained 24 hours after the accident. Subsequently, the patient was operated 
on every second day (VAC system), until the abdomen was closed definitively. After almost 
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1 month of intensive care, the patient was transferred to a normal ward, from which he was 
discharged after 2 weeks.  
Eight months after the accident, the patient felt comfortable and increasingly strong. From a 
clinical perspective, the patient was in good condition with good cardiopulmonary function 
and no neurological or behavioural deficiencies. There was a perfect perfusion of the sutured 
abdominal aorta with stable dissection membrane by computed tomography (angiography), 
and no clinical signs of claudicatio, abdominal angina or peripheral arterial occlusive 
disease.  
Discussion 
This case report demonstrates successful use of ROTEM for detection of hyperfibrinolysis 
and guidance of treatment with antifibrinolytics and fibrinogen concentrate, in severe blunt 
abdominal trauma. Although there was coagulopathy due to blood loss and dilution, we did 
not need to administer FFP or platelets. This represents significant reduction in the use of 
allogeneic products compared with standard practice in most clinics, thereby minimising the 
risks to which the patient was exposed. 
By using ROTEM, excessive hyperfibrinolysis was identified and treated within minutes of 
patient’s arrival. It has to be pointed out that in case of proven or highly suspected 
hyperfibrinolysis, antifibrinolytic agent is not only justified but has to be administered before 
administration of any other procoagulant treatment. Therefore, the patient in our case report 
first received tranexamic acid and only by then, fibrinogen was administered. 
It is also notable that normal ROTEM results after surgery correlated with stable clinical 
condition, but laboratory results showed high INR and extended aPTT – this indicates that 
ROTEM results provide a better guide for treatment decisions. Due to very rapid surgical 
controlling of the haemorrhage by clamping and suturing the aorta and the administration of 
antifibrinolytic medication, more severe coagulopathy was prevented. 
It is of interest that this patient could be treated with limited administration of blood 
products. As fibrinogen is the first coagulation factor to reach critically low levels, it is logical 
that this should be the primary coagulation factor to be supplemented. In a previous study 
examining blood samples with low platelet counts, fibrinogen has been shown to be effective 
in samples with low platelet counts.20 It was shown that the clot strength increases in a 
fibrinogen concentration-dependent manner independent of platelet count, when analyzed 
by ROTEM. Thereby, the maintenance of fibrinogen concentration has been shown to be 
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critical in the presence of thrombocytopenia.20 Although large scale clinical studies are 
lacking to define the optimal dosage and timing of fibrinogen administration so far, several 
recent studies now pointing toward the true effectiveness of early fibrinogen administration 
in reversing dilutional coagulopathy, resulting in reduced requirement for postoperative 
transfusion.14,15 In the present case, platelets did not drop to levels low enough to warrant 
supplementation, but even if they had dropped there is a good chance that platelets would 
still have not been needed. In addition to fibrinogen therapy, there is evidence that early 
supplementation of factor XIII can improve clot firmness.21 Factor XIII is the key coagulation 
factor to stabilize the clot. There is a relation between decreased factor XIII activity and 
reduced clot firmness. Trauma and major hemorrhage is known to be a cause of acquired 
factor XIII deficiency. It seems therefore reasonable to substitute factor XIII early (if levels fall 
below 60%), thereby improving clot firmness, reducing bleeding and minimizing the use of 
blood products.22 
More advanced dilutional coagulopathy may necessitate supplementation of coagulation 
factors other than fibrinogen and factor XIII. This can be achieved in general by 
administering fresh frozen plasma or whole blood. As with platelet concentrate, there are 
however several potential drawback of these transfusions like transfusion associated lung 
injury (TRALI), increased risk of infection, sepsis, transfusion related circulatory overload 
(TACO) and finally variable haemostatic effects. One alternative option without these 
negative adverse events in these circumstances would therefore be to administer PCC and or 
other specific coagulation factor concentrates. 
Although very useful, several potential limitations of ROTEM technology have to be 
considered.17 Conventional ROTEM tests are not sensitive to targeted pharmacological 
platelet inhibition. Therefore, effects of aspirin or clopidogrel on platelets for example cannot 
be detected by ROTEM so far. For TEG however, a more sophisticated test has recently been 
developed to specifically determine platelet function in the presence of antiplatelet therapy 
(PlateletMappingTM). Furthermore, ROTEM currently has no commercial reagents directed on 
guiding usage of specific coagulation factor concentrates other than fibrinogen (such as FXIII, 
PCC, and rFVIIa).  
The treatment approach described in this case report appears to be a promising method for 
reducing transfusion of allogeneic blood products. It is also notable that improved ROTEM 
results after the surgery correlated with a more stable clinical condition, whereas the 
standard laboratory results were abnormal. It may therefore be speculated that ROTEM 
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results provide a better guide for treatment decisions compared to standard laboratory 
parameters. 
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Tables 
Table 1. Haematological analyses performed at different time points. 
Time Parameter 
13:30 17:45 24 hours after 
the accident 
44 hours after 
the accident 
Platelet count 
(platelets/µl) 
115,000 149,000 N/A 93,000 
Haemoglobin (g/dl) 9.7 10.3 N/A 6.7 
Haematocrit (%) 27.6 29.6 N/A 18.9 
Quick (%) 22 38 43 34 
International 
normalised ratio (INR) 
2.7 1.7 1.6 2.0 
Activated partial 
thromboplastin time 
(aPTT, seconds) 
>200 67 44 60 
Prothrombin time 
(seconds) 
25 N/A N/A N/A 
Fibrinogen (g/l) 2.1 2.3 2.5 2.4 
Factor II activity (%) N/A 18 28 21 
Factor V activity (%) N/A <10 32 31 
Factor VII activity (%) N/A 32 22 12 
N/A, not available. 
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Figures 
Figure 1. Time line of events presented in this case report. 
 
 
Figure 2. Fulminant hyperfibrinolysis and hypofibrinogenaemia in the first ROTEM analysis. 
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Figure 3. ROTEM analysis after administration of 1 g tranexamic acid and 4 g fibrinogen 
concentrate. 
 
 
 
 
Figure 4. ROTEM analysis after administration of additional 4 g fibrinogen concentrate. 
 
 
 
 
